Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir. Gilead's bictegravir, another so-called integrase inhibitor drug, delivered 97 percent virus suppression, making it just as effective as GSK's product, data presented at a medical meeting in Seattle late on Monday showed. Importantly, there were no cases of resistance emerging to the new medicine in the 98-patient Phase II study and no patients discontinued treatment due to kidney problems, which can be an issue with HIV treatments.
Kidneys from older donors — living or deceased — can last for at least five years, providing some people on the kidney wait list with another viable option.
A pilot study looks at transplanting hepatitis C-positive kidneys into people without the virus. The theory is it’s easier to deal with hepatitis than a diseased kidney.
Researchers say that roller coasters may help pass kidney stones. It’s not the first offbeat remedy to be proposed for serious medical conditions.